Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluticasone Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 14/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
| ▸ | CNR1 | P21554 | 1/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluticasone Propionate SCHEMBL14343427 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL15325049 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL4283 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL15944858 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL4111260 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL13993454 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL191134 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL14339613 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL5482829 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL13602403 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220054715-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | UNIV EMORY (US) | 2022-02-24 | — | — | US | disclosed |
| US-11179501-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | EMORY UNIVERSITY (US) | 2021-11-23 | — | — | US | disclosed |
| EP-2402361-B1 | PROCESS FOR THE PREPARATION OF S-FLUOROMETHYL-6,9-DIFLUORO-11-HYDROXY-16-METHYL-17-PROPIONYLOXY-3-OXO-ANDROSTA-1,4-DIENE-17-CARBOTHIOATE AND INTERMEDIATES | GENERICS UK LTD (GB) | 2020-04-15 | — | — | EP | disclosed |
| EP-2402360-B1 | Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1,4-diene-17-carbothioate and intermediates | GENERICS UK LTD (GB) | 2020-04-01 | — | — | EP | disclosed |
| US-20190224378-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | UNIV EMORY (US) | 2019-07-25 | — | — | US | disclosed |
| US-10286113-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | EMORY UNIVERSITY (US) | 2019-05-14 | — | — | US | disclosed |
| US-20160361470-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | UNIV EMORY (US) | 2016-12-15 | — | — | US | disclosed |
| US-20140248372-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2013043529-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-03-28 | — | — | WO | disclosed |
| EP-2044099-B1 | PROCESS FOR THE PREPARATION OF S-FLUOROMETHYL-6 ,9 -DIFLUORO-11 -HYDROXY-16 -METHYL-17 -PROPIONYLOXY-3-OXO-ANDROSTA-1,4-DIENE-17 -CARBOTHIOATE AND INTERMEDIATES | GENERICS UK LTD (GB) | 2012-05-23 | — | — | EP | disclosed |
| EP-2402360-A1 | Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1,4-diene-17-carbothioate and intermediates | Generics (UK) Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402361-A1 | Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1,4-diene-17-carbothioate and intermediates | Generics (UK) Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| EP-2044099-A2 | PROCESS FOR THE PREPARATION OF S-FLUOROMETHYL-6 ,9 -DIFLUORO-11 -HYDROXY-16 -METHYL-17 -PROPIONYLOXY-3-OXO-ANDROSTA-1,4-DIENE-17 -CARBOTHIOATE AND INTERMEDIATES | Merck Generics (UK) Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007144668-A3 | PROCESS FOR THE PREPARATION OF S-FLUOROMETHYL-6, 9 -DIFLUORO-11 -HYDROXY-16 -METHYL-17-PROPIONYLOXY-3-OXO-ANDROSTA-1,4-DIENE-17 -CARBOTHIOATE AND INTERMEDIATES | GENERICS UK LTD (GB) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007144668-A2 | PROCESS FOR THE PREPARATION OF S-FLUOROMETHYL-6, 9 -DIFLUORO-11 -HYDROXY-16 -METHYL-17-PROPIONYLOXY-3-OXO-ANDROSTA-1,4-DIENE-17 -CARBOTHIOATE AND INTERMEDIATES | GENERICS [UK] LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361470-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | BMP4, SOST, BMP2 | NR3C1 680/4885PGR 1508/4885AR 1121/4885 |
| US-20190224378-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | BMP4, SOST, BMP2 | NR3C1 680/4885PGR 1508/4885AR 1121/4885 |
| US-20140248372-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | BMP4, SOST, BMP2 | NR3C1 680/4885PGR 1508/4885AR 1121/4885 |
| US-20220054715-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | BMP4, SOST, BMP2 | NR3C1 680/4885PGR 1508/4885AR 1121/4885 |
| US-11179501-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | BMP4, SOST, BMP2 | NR3C1 680/4885PGR 1508/4885AR 1121/4885 |
| US-10286113-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | BMP4, SOST, BMP2 | NR3C1 680/4885PGR 1508/4885AR 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.